Active Ingredients: Isotretinoin
Thirty two subjects from group I received isotretinoin at the dose of 0. In, Amichai et al.
The patients were divided into 2 groups according to age: group I — patients aged between 12 and 20 years, and group II — patients aged from 21 to 35 years.
Twenty two patients out of 638 stopped the treatment.
Improvement in skin lesions was observed, in group I in 94. Within a 4-year observation period, recurrence was found in 3.
A similar therapeutic regimen was used by Sardana et al. Prospective studies were carried out on 320 patients diagnosed with moderately severe acne. The study was followed by a 6-month observation period.
The study was completed by 305 patients. The average cumulative dose taken by patients was 38. Within a 6-month observation period, recurrences occurred in 50 16.
In, Lee et al. Sixty patients with moderate acne were qualified for the study. The subjects were divided into 3 groups; patients in group A were given isotretinoin at the dose of 0. Efficacy, tolerability of the therapy and patient satisfaction were compared in all groups.
The therapy was followed by 1 year of observation.
The number of both inflammatory and non-inflammatory lesions was statistically significantly different in groups B and C as well as C and A whereas there were no statistically significant differences between groups A and B, which suggests that conventional therapy and therapy with low doses of isotretinoin are similarly effective.
Patient satisfaction scores were the highest in group B low doses of the drug, lower in group C intermittent therapy and the lowest in group A conventional therapy.
Adverse effects occurred most commonly in patients treated with the use of conventional method group A, compared to the groups treated with low doses of isotretinoin group B and intermittent method group C.
In, Rasi et al.